Tag Archives: Risky

FDA Gives Accelerated Approval for Risky Alzheimer’s Pill

The U.S. Food and Drug Administration granted accelerated approval for the Alzheimer’s disease drug lecanemab (Leqembi). The drug, a monoclonal antibody, binds to amyloid beta in the brain. An 18-month study published in the New England Journal of Medicine1 found Leqembi reduced markers of amyloid in early Alzheimer’s disease and led to “moderately less decline”… Read More »